The Motley Fool

3 Reasons Why I’m Bullish On AstraZeneca plc

AstraZeneca (LSE: AZN) (NYSE: AZN.US) has been in the headlines a lot in recent years because of its ‘patent cliff’.

For those Fools who aren’t up to speed on what this is, it’s basically a lack of new drugs coming on stream to replace the ones that are set to go off-patent. In other words, AstraZeneca has a lack of new revenue streams to replace the revenue streams that are no longer going to be protected by patents.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Clearly, this is a major problem for a drugs company that relies on patents to protect its margins and, ultimately, its profits.

However, the ‘patent cliff’ has been known about for several years, with AstraZeneca’s shares being hit as a result of concerns surrounding it.

For me, though, this presents an ideal opportunity to buy shares in a fantastic turnaround story for three key reasons.

Firstly, shares offer a fantastic yield of 6%. This puts them at the top table of high-yielding shares and means that AstraZeneca is an obvious choice for income investors like me.

Indeed, a yield of 6% is more than three times what I can get in a savings account and is more than double the rate of inflation.

Furthermore, dividends per share are very well covered and, even with the considerable fall in earnings priced in, dividends look set to be well covered for a good while yet. This offers at least a degree of stability and peace of mind to shareholders.

Secondly, new management has adopted a much more aggressive strategy with regards to overcoming the ‘patent cliff’. They have ended the share-buyback programme and set about buying up the rights to other drugs so as to try and rebuild the aforementioned declining revenue streams.

Although it will take time for the strategy to come to fruition, it looks set to.

Thirdly, AstraZeneca is a defensive stock with a low beta. This means that, with the FTSE 100 being within 5% of its all-time high and having a high price-to-earnings (P/E) ratio of 15, AstraZeneca could prove to be a sound option should markets fall.

So, I’m bullish on AstraZeneca due to its well-covered and impressive yield, sound strategy and defensive qualities. The fact that it is a great income stock, though, is probably the key, key reason, of course.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

> Peter owns shares in AstraZeneca.

Our 6 'Best Buys Now' Shares

The renowned analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply enter your email address below to discover how you can take advantage of this.

I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.